Your SlideShare is downloading. ×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply



Published on

The Indian Pharmaceutical sector has been on a roll ever since the global economy picked itself up post the 2007 mayhem. Given the strong fundamentals of the Indian Pharmaceutical industry and the …

The Indian Pharmaceutical sector has been on a roll ever since the global economy picked itself up post the 2007 mayhem. Given the strong fundamentals of the Indian Pharmaceutical industry and the global opportunity due to the patent cliff in the western world, listed pharmaceutical stocks have responded well and rallied substantially. While the international opportunities have been good for the bottom line, pharmaceutical stocks with a larger or significant share of the domestic pharma market have come in for a rude shock as the implementation of the new pricing policy outline of the NPPA can sharply erode profitability. As the policy elements are still not clear, it would be premature to judge how individual companies would be affected.

With a view to having a mid journey outlook on expected price performance of pharmaceutical stocks, we decided to conduct a study of the major pharmaceutical stocks using technical analysis and analyse which stocks offer the best opportunity both from a long and short point of view. The exhaustive analysis was done on 29 of the major stocks, the details of which one can obtained from the slideshow.

The analysis was done using weekly chart data to get a more longer term picture and some of the results we found were quite contrary to general market expectation; yet others were quite revealing of exciting investment opportunities. We could have easily summed up our analysis and provided an instant listing of our analysis and recommendations for the benefit of our blog readers, but we thought it more appropriate that the reader “visualize” our analysis as “one picture is worth more than a thousand words.”

Technical analysis is a great science for stock price forecasting, but the overall investment decision can be more solid if backed by hard core fundamental study. In part 2 of the Indian Pharmaceutical Outlook, we would be providing extremely high quality fundamental evaluation on the fortunes of these very 29 stocks so that our faithful blog readers can make investment decisions based on comprehensive analysis.

As with all the content on this blog, the report will be provided FREE. However in order to make a point of the exclusivity of the content, we request blog readers to send us an email so that we could deliver it directly in your email inbox. This we request so that we could obtain your feedback on the same report so that we can improve on the content. We would also like to solicit your opinion on the type of content that readers find interesting so that future blog posts could be based more on reader interest rather than just what we think you should read.

Published in: Economy & Finance
1 Like
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. About Winning Trades Winning Trades ( offers a unique proposition of identifying high yield financial investment /trading ideas with an emphasis on minimizing risk WT is owned and run by Vinit Bolinjkar who has over 16 years of experience in financial markets To get in touch: Email: Phone: +91-9730836363 Other individual experts also contribute content to WT.
  • 2.  Pharma stocks have had a dream run and outperformed the markets by a wide margin since the beginning of this decade. With the patent cliff playing out globally they are expected to continue to do well throughout the decade. This slide show identifies opportune times to buy individual pharma stocks using technical analysis.
  • 3. Stocks discussed in this slideshowAjanta Pharma Ltd Glaxosmithkline Pfizer Ltd Pharmaceuticals LtdAlembic Pharmaceuticals Ltd Ranbaxy Laboratories Ltd Glenmark Pharmaceuticals Ltd RPG Life Sciences LtdAurobindo Pharma Ltd IPCA Laboratories Ltd Shasun Pharmaceuticals LtdBiocon Ltd Jubilant Life sciences Ltd Strides Arcolab LtdCadila Healthcare Ltd Lupin Ltd Sun PharmaceuticalCipla Ltd Merck Ltd Industries LtdDishman Pharmaceuticals andChemicals Ltd Natco Pharma Ltd Torrent Pharmaceuticals LtdDivi’s Laboratories Ltd Orchid Chemicals & Unichem Laboratories Ltd Pharmaceuticals LtdDr Reddy’s Laboratories Ltd Vivimed Labs Ltd Panacea Biotec LtdElder Pharmaceuticals Ltd Wockhardt Ltd Wyeth Ltd
  • 4. Ajanta Pharma Ltd
  • 5. Alembic Pharmaceuticals Ltd
  • 6. Aurobindo Pharma Ltd
  • 7. Biocon Ltd
  • 8. Cadila Healthcare Ltd
  • 9. Cipla Ltd
  • 10. Dishman Pharmaceuticals Chemicals Ltd
  • 11. Divi’s Laboratories Ltd
  • 12. Dr Reddy’s Laboratories Ltd
  • 13. Elder Pharmaceuticals Ltd
  • 14. Glaxosmithkline Pharmaceuticals Ltd
  • 15. Glenmark Pharmaceuticals Ltd
  • 16. IPCA Laboratories Ltd
  • 17. Jubilant Life Sciences Ltd
  • 18. Lupin Ltd
  • 19. Merck Ltd
  • 20. Natco Pharma Ltd
  • 21. Orchid Chemicals & Pharmaceuticals Ltd
  • 22. Panacea Biotec Ltd
  • 23. Pfizer Ltd
  • 24. Ranbaxy Laboratories Ltd
  • 25. RPG Life Sciences Ltd
  • 26. Shasun Pharmaceuticals Ltd
  • 27. Strides Arcolab Ltd
  • 28. Sun Pharmaceutical Industries Ltd
  • 29. Torrent Pharmaceuticals Ltd
  • 30. Unichem Laboratories Ltd
  • 31. Vivimed Labs Ltd
  • 32. Wockhardt Ltd
  • 33. Wyeth Ltd
  • 34. For a FREE Copy of theIndian Pharma Sector: Fundamental Outlook Send us an email at:
  • 35. Disclaimer:The views expressed in this article are entirely my own and do not reflect theviews of my employer. This report is neither an offer nor a solicitation to purchaseor sell securities. The information and views expressed herein are believed to bereliable, but no responsibility (or liability) is accepted for errors of fact or opinion.Writers and contributors may be trading in or have positions in the securitiesmentioned in their articles. Neither or myself acceptsany liability arising out of the above information / articles.